The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study
- PMID: 19945740
- DOI: 10.1016/j.ygyno.2009.10.073
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study
Abstract
Objectives: A prior clinical trial on early-stage high risk ovarian cancer showed a lower recurrence rate in those treated with six vs. three cycles of chemotherapy. We proposed to identify subsets of patients who may benefit from more cycles of chemotherapy.
Methods: Outcomes of patients who underwent six vs. three cycles of chemotherapy were analyzed based on clinico-pathologic factors. Kaplan-Meier estimates and Cox Regression Model were used for analyses.
Results: Of 427 patients (median age: 55 years), 69% had stage I disease, 30% had clear cell, 25% endometrioid, 23% serous, 7% mucinous, and 15% had other cell types. The risk of recurrence in those who had six vs. three cycles of chemotherapy was not different based on age, performance status, stage, grade of disease, presence of ascites, tumor rupture, or positive cytology. However, those with serous tumors had a significantly lower risk of recurrence after six vs. three cycles of chemotherapy (HR=0.33, CI=0.14-0.77; p=0.04) in contrast to non-serous tumors (HR=0.94, CI=0.60-1.49). Nevertheless, a test of homogeneity did not show a difference in treatment effects across cell types (p=0.285). Of those with serous tumors, the 5-year recurrence-free survival was 83% and 60% in those who received six vs. three cycles of chemotherapy, respectively (p=0.007).
Conclusions: In this exploratory analysis of early-stage high risk ovarian cancer, our data suggest that six rather than three cycles of chemotherapy may decrease the recurrence of patients with serous tumors. Further studies are needed to confirm these findings.
Similar articles
-
Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary.Gynecol Oncol. 2014 Mar;132(3):760-6. doi: 10.1016/j.ygyno.2014.01.012. Epub 2014 Jan 16. Gynecol Oncol. 2014. PMID: 24440832 Review.
-
Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.Gynecol Oncol. 2010 Mar;116(3):307-11. doi: 10.1016/j.ygyno.2009.10.074. Epub 2009 Nov 27. Gynecol Oncol. 2010. PMID: 19944452 Clinical Trial.
-
For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?Am J Clin Oncol. 2008 Feb;31(1):39-42. doi: 10.1097/COC.0b013e318134ee6f. Am J Clin Oncol. 2008. PMID: 18376226
-
Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.Cancer. 2008 May 15;112(10):2202-10. doi: 10.1002/cncr.23390. Cancer. 2008. PMID: 18348296 Clinical Trial.
-
Gynecological malignancies.Cancer Chemother Biol Response Modif. 1996;16:564-91. Cancer Chemother Biol Response Modif. 1996. PMID: 8639401 Review.
Cited by
-
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.J Ovarian Res. 2024 Feb 12;17(1):39. doi: 10.1186/s13048-024-01359-7. J Ovarian Res. 2024. PMID: 38347608 Free PMC article. Review.
-
The Role of Interleukin 6 (IL6), Cancer Antigen-125 (CA-125), and Human Epididymis Protein 4 (HE4) to predict tumor resectability in the advanced epithelial ovarian cancer patients.PLoS One. 2023 Oct 4;18(10):e0292282. doi: 10.1371/journal.pone.0292282. eCollection 2023. PLoS One. 2023. PMID: 37792745 Free PMC article.
-
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options.Drugs. 2023 Oct;83(15):1365-1385. doi: 10.1007/s40265-023-01934-0. Epub 2023 Sep 22. Drugs. 2023. PMID: 37737434 Free PMC article. Review.
-
Clinical and translational advances in ovarian cancer therapy.Nat Cancer. 2023 Sep;4(9):1239-1257. doi: 10.1038/s43018-023-00617-9. Epub 2023 Aug 31. Nat Cancer. 2023. PMID: 37653142 Review.
-
Impact of the number of cycles of platinum-based chemotherapy for early stage ovarian clear cell carcinoma on survival: a retrospective study.BMC Womens Health. 2023 May 15;23(1):262. doi: 10.1186/s12905-023-02405-0. BMC Womens Health. 2023. PMID: 37189098 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical